Jefferies Financial Group Reiterates “Buy” Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)‘s stock had its “buy” rating restated by equities research analysts at Jefferies Financial Group in a research note issued on Monday,London Stock Exchange reports. They presently have a £175 price target on the biopharmaceutical company’s stock. Jefferies Financial Group’s target price suggests a potential upside of 47.85% from the stock’s current price.

Several other brokerages have also recently weighed in on AZN. Citigroup lifted their price target on shares of AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a research note on Tuesday, July 28th. Berenberg Bank restated a “buy” rating and issued a £160 price objective on shares of AstraZeneca in a research note on Tuesday, July 28th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating and issued a £115 target price on shares of AstraZeneca in a report on Tuesday, July 28th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of £152.17.

AstraZeneca Stock Performance

Shares of LON AZN opened at £118.36 on Monday. The firm has a 50 day moving average of £134.04 and a 200 day moving average of £140.23. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 64.10. The firm has a market capitalization of £183.56 billion, a price-to-earnings ratio of 17.83, a price-to-earnings-growth ratio of 0.86 and a beta of 0.23. AstraZeneca has a 12-month low of £107.84 and a 12-month high of £157.32.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.